Effect of hepatitis B and C clearance on atazanavir exposure

@article{Gervasoni2015EffectOH,
  title={Effect of hepatitis B and C clearance on atazanavir exposure},
  author={Cristina Gervasoni and Dario Cattaneo and Valeria Micheli and Valentina Di Cristo and Laura Milazzo},
  journal={European Journal of Clinical Pharmacology},
  year={2015},
  volume={71},
  pages={1409 - 1411}
}

References

SHOWING 1-10 OF 12 REFERENCES

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

A reduction in CYP3A4 activity is demonstrated between healthy volunteers and patients with CHC, with interferon null-responders demonstrating the most substantial difference, which may have implications for the pharmacotherapy of patients infected withCHC.

Clinical pharmacology, efficacy and safety of atazanavir: a review

The combination of a similar efficacy, a better tolerance and a low pill burden, as compared to other PIs, makes boosted ATV one of the best options, in combination with NRTIs, in PI-naive HIV-1 infected patients.

Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions

Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic–pharmacodynamic relationships.

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?

These patients that are at high risk to experience ATV-related complications may benefit from TDM-driven adjustments in ATV dosage with potential advantages in terms of costs and toxicity.

High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.

Urinary crystals were found in a few patients receiving ritonavir-boosted atazanavir or darunavir and may favour nephrolithiasis and be associated with kidney stones and renal failure.

Effects of interferon-α on cytochrome P‐450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C

The suggestion that drugs metabolized by these isoenzymes may be used together with interferon-a in patients with chronic hepatitis C without significant risks of drug interactions is supported.

Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C.

The results support the suggestion that drugs metabolized by these isoenzymes may be used together with interferon-alpha in patients with chronic hepatitis C without significant risks of drug interactions.

Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis

Results suggest that alterations in phenotypic expression of specific P-450 isoenzymes in hepatocytes associated with hepatic inflammation and cirrhosis might increase susceptibility to AFB genotoxicity.

Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis.

  • Y. NiuZheng Wu Wenxin Qin
  • Biology, Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2013